Perceptive Advisors LLC raised its stake in Iovance Biotherapeutics Inc (NASDAQ:IOVA) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,776,114 shares of the biotechnology company’s stock after acquiring an additional 50,000 shares during the quarter. Iovance Biotherapeutics makes up approximately 1.3% of Perceptive Advisors LLC’s investment portfolio, making the stock its 19th largest position. Perceptive Advisors LLC owned approximately 0.06% of Iovance Biotherapeutics worth $38,208,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in IOVA. Parametric Portfolio Associates LLC acquired a new position in Iovance Biotherapeutics in the second quarter valued at approximately $125,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Iovance Biotherapeutics during the 3rd quarter worth approximately $133,000. Ellington Management Group LLC raised its stake in shares of Iovance Biotherapeutics by 39.1% during the 4th quarter. Ellington Management Group LLC now owns 19,200 shares of the biotechnology company’s stock worth $154,000 after buying an additional 5,400 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $154,000. Finally, Jane Street Group LLC acquired a new position in shares of Iovance Biotherapeutics during the 3rd quarter worth approximately $164,000. 67.82% of the stock is owned by institutional investors.
Iovance Biotherapeutics Inc (IOVA) opened at $19.10 on Monday. Iovance Biotherapeutics Inc has a 52 week low of $4.45 and a 52 week high of $19.60. The company has a market capitalization of $1,660.84, a price-to-earnings ratio of -14.69 and a beta of 5.57.
COPYRIGHT VIOLATION WARNING: “Perceptive Advisors LLC Has $38.21 Million Holdings in Iovance Biotherapeutics Inc (IOVA)” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://sportsperspectives.com/2018/03/12/perceptive-advisors-llc-has-38-21-million-holdings-in-iovance-biotherapeutics-inc-iova.html.
Iovance Biotherapeutics Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics Inc (NASDAQ:IOVA).
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.